Jiangxi Rimag Group (2522) Fair Value & Analysis
Healthcare · HK · Market cap HK$1.8B
Fair value as of: Aug 13, 2026
From 24 valuation models · updated today
Fair value updated Aug 13, 2026, revised from HK$0.3200 to HK$2.51 (+684.4%) since Jul 7, 2026. Share price −8.9% over the past month.
Below-average quality, and screening another 46% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$3.45). The favourable scenario is already priced in.
- Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (HK$1.41 to HK$3.45) leaves room in how you read the outcome.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
26‑month range HK$4.45 – HK$70.80 · fair‑value band HK$1.41 – HK$3.45 · the HK$4.66 price screens above the HK$2.51 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Jiangxi Rimag Group (2522) currently trades at HK$4.66, while our model-based Fair Value estimate is HK$2.51, implying the stock looks roughly 46.1% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Jiangxi Rimag Group generated revenue of HK$873M at a net margin of 0.4%. Revenue grew 17.1% year over year. It earns a return on equity of -0.6%. The balance sheet holds a net cash position of HK$1.3M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$1.41 (bear case) to HK$3.45 (bull case); at HK$4.66, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -12% fair-value upside, at -46%, 2522 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Asset-Based (HK$3.73) versus Earnings-Based (HK$0.1000). Highest evidence: Growth DCF (80).
Notify me when 2522 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jiangxi Rimag Group Co., Ltd., together with its subsidiaries, invests in and operates medical imaging centers in Mainland China, Hong Kong, Macau, and internationally. It operates through Imaging Center Services, Imaging Solution Services, and Digital-Intelligent Services segments.
Full company description
Jiangxi Rimag Group Co., Ltd., together with its subsidiaries, invests in and operates medical imaging centers in Mainland China, Hong Kong, Macau, and internationally. It operates through Imaging Center Services, Imaging Solution Services, and Digital-Intelligent Services segments. The company offers imaging examination and diagnostic imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy, and other related procedures to hospitals and other medical institutions, health management companies, individual patients, and other healthcare customers; medical imaging operational management services; imaging equipment and software solutions; imaging capability improvement services; imaging empowerment solutions, such as equipment selection and configuration, quality control, remote consultation, medical staff training, clinical imaging capability analysis, and repair services. It also provides Rimag Cloud services, including cloud storage and cloud film modules, remote diagnosis and consultation for complex cases, remote hosting services, imaging AI integration platform, refined operation management modules, cloud radiology information system (RIS) modules, and quality control modules; data processing and analysis solutions; and remote and AI diagnosis services. In addition, the company engages in the operation and management of a medical imaging cloud platform that provides diversified imaging services; operation of a research and development center; technical support; sale of medical devices and consumables; clinic services; maintenance and installation of medical equipment; technology development of medical imaging cloud platforms; and medical imaging industry chain services. Jiangxi Rimag Group Co., Ltd. was incorporated in 2014 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jiangxi Rimag Group reported revenue of HK$873M in FY2025 versus HK$592M in FY2021, a compound +10.2%/yr. Reported net income was HK$3.7M in FY2025.
2522 screens 46% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 263 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,103 | ₹284.87 | -74% |
Compare Jiangxi Rimag Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jiangxi Rimag Group (2522) overvalued or undervalued?
What is the fair value of 2522?
What is the quality score of 2522?
What is the revenue of Jiangxi Rimag Group (2522)?
What is the net profit margin of 2522?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jiangxi Rimag Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.